SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 31 of 94
Word Count: 1365
Character Count: 8717

Document Content:

and if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which could cause our stock price and trading volume to decline. Future sales of our common stock or securities convertible, exchangeable or exercisable into our common stock may depress our stock price. Sales of a substantial number of shares of our common stock or securities convertible, exchangeable or exercisable into our common stock in the public market after the completion of this offering, or the perception that these sales could occur, could adversely affect the market price of our common stock and could materially impair our ability to raise capital through equity offerings in the future.

The
common stock sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933,
as amended (the “Securities Act”), and shares held by our existing stockholders may also be sold in the public market in
the future subject to the restrictions in Rule 144 under the Securities Act and the applicable lock-up agreements. Following the consummation
of this offering, assuming no exercise of outstanding options or the Underwriters’ Warrants, there will be
shares of common stock outstanding immediately after this offering assuming full exercise of the underwriters’ over-allotment option,
and shares of common stock assuming no exercise of the underwriters’ over-allotment option, including 7,943,927 shares of
common stock being issued upon the closing of this offering in connection with the conversion of: (i) 1,302,950 shares of our
existing Series A Preferred Stock into 1,302,950 shares of common stock (assuming an initial public offering price of at least
$10.00 and an assumed conversion price of $10.00) and (ii) $12,797,898 of our existing convertible notes into 6,640,977
shares of our common stock (assuming an initial public offering price of at least $10.00 and an assumed conversion price of $10.00).
In connection with this offering, we and each of our directors and officers named in the section “Management,” and
our existing stockholders have agreed not to sell shares of common stock for a period of six (6) months from the date of the closing
of this offering without the prior written consent of the representative of the underwriters, subject to customary exceptions. The representative
of the underwriters may release these securities from lock-up restrictions at any time, subject to applicable regulations of the Financial
Industry Regulatory Authority, Inc. (“FINRA”). We cannot predict what effect, if any, market sales of securities held by
our significant stockholders or any other stockholder or the availability of these securities for future sale will have on the market
price of our common stock. See “Underwriting” and “Shares Eligible for Future Sale” for a more
detailed description of the restrictions on selling our securities after this offering.

Our
failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock.

There
is a risk that our securities will not continue to be listed on Nasdaq even if our securities are listed on Nasdaq. Following this offering,
in order to maintain our listing on Nasdaq, we will be required to comply with certain Nasdaq continuing listing rules, including those
regarding minimum stockholders’ equity, minimum share price, minimum market value of publicly held shares, corporate governance
and various additional requirements. If we are unable to satisfy Nasdaq criteria for maintaining our listing, our securities could be
subject to delisting. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability
to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action
taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market
price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement
or prevent future non-compliance with Nasdaq’s listing requirements.

Our
management will have broad discretion in how we use the net proceeds from this offering and might not use them effectively.

Our
management will have considerable discretion over the use of proceeds from this offering. We currently intend to use the net proceeds
from this offering primarily to fund the RELIVE Trial and the associated manufacturing activities required to support such trial. The
remaining portion of the net proceeds will be used to fund working capital and general administrative expenses. You will not have the
opportunity, as part of your investment decision, to assess whether the proceeds are being used in a manner which you may consider most
appropriate. Our management might spend a portion or all of the net proceeds from this offering in ways that our stockholders do not
desire or that do not necessarily improve our operating results or enhance the value of our common stock. The failure of our management
to apply these proceeds effectively could, among other things, result in unfavorable returns and uncertainty about our prospects, each
of which could cause the price of our common stock to decline.

You
will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future.

You
will incur immediate and substantial dilution as a result of this offering. After giving effect to the sale by us of             shares
in this offering at an assumed initial public offering price of $          per share (the
midpoint of the estimated price range set forth on the cover page of this prospectus), and after deducting underwriting discounts and
estimated offering expenses payable by us, investors in this offering can expect an immediate dilution of $         per
share at the assumed initial public offering price. Additionally, to the extent that warrants (including the Underwriters’ Warrants),
or options we will grant to our officers, directors and employees, are ultimately exercised, you will sustain future dilution. We may
also acquire new businesses or finance strategic alliances by issuing equity, which may result in additional dilution to our stockholders.
Following the completion of this offering, our board of directors has the authority, within any limitations prescribed by relevant laws
and our charter documents, to issue all or any part of our authorized but unissued shares of common stock, including shares issuable
upon the exercise of options, or shares of our authorized but unissued preferred stock. Issuances of common stock or voting preferred
stock would reduce your influence over matters on which our stockholders vote and, in the case of issuances of preferred stock, would
likely result in your interest in us being subject to the prior rights of holders of that preferred stock. See the section titled “Dilution.”

will incur significant costs as a result of operating as a public company and our management expects to devote substantial time to public
company compliance programs.

a public company, we will incur significant legal, accounting and other expenses due to our compliance with regulations and disclosure
obligations applicable to us, including compliance with the Sarbanes-Oxley Act, as well as rules implemented by the SEC and Nasdaq. Shareholder
activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial
new regulations and disclosure obligations, which may lead to additional compliance costs and impact, in ways we cannot currently anticipate,
the manner in which we operate our business. Our management and other personnel will devote a substantial amount of time to these compliance
programs and monitoring of public company reporting obligations and as a result of the new corporate governance and executive compensation
related rules, regulations and guidelines prompted by the Dodd-Frank Act and further regulations and disclosure obligations expected
in the future, we will likely need to devote additional time and costs to comply with such compliance programs and rules. These rules
and regulations will cause us to incur significant legal and financial compliance costs and will make some activities more time-consuming
and costly.